LEADERSHIP R & D CLINICAL DEVELOPMENT PATIENTS INVESTORS NEWSROOM CAREERS CONTACT US HOME
WELCOME
 
 

Revolutionizing Regenerative Medicine


BioMimetic Therapeutics, Inc. is an emerging leader in the development and commercialization of drug-device combination products for the repair of orthopedic injuries to bone, cartilage, ligaments and tendons. BioMimetic's suite of products and product candidates combine recombinant protein therapeutics with tissue specific scaffolds, actively stimulating tissue healing and regeneration. BioMimetic believes its biologically-enhanced orthopedic therapies can improve the treatment options and quality of life for millions of patients suffering injuries or deterioration of the bones, cartilage (joints), ligaments and tendons.


 
Recent BioMimetic Therapeutics Announcements

BioMimetic Therapeutics, Inc. Announces Completion of Rights Offering and Sale of Shares in Standby Purchase
 
BioMimetic Therapeutics Announces Highlights from Annual Meeting of Stockholders
 
BioMimetic Therapeutics Submits First Two PMA Modules to FDA; Company Receives ISO 9001 Certification and ISO 13485 Recertification
 
BioMimetic Therapeutics, Inc. Announces Extension of Rights Offering
 
BioMimetic Therapeutics, Inc. Announces Launch of Rights Offering
 
BioMimetic Therapeutics Releases 2009 First Quarter Financial Results
 
BioMimetic Therapeutics, Inc. Announces an $8 Million Private Placement; Company Intends to Commence Rights Offering
 
BioMimetic Therapeutics, Inc. Announces Record Date for Rights Offering
 
 
Obtain a current stock quote for BioMimetic Therapeutics, Inc. (NASDAQ : BMTI)


View an interactive version of the BMTI Annual Report
BioMimetic Therapeutics, Inc. For more information, please e-mail us.
Website development and managed hosting by Acuity Marketing Communications, Inc.